Etoposide-induced DNA cleavage in human leukemia cells

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Topoisomerase II is a critical target for chemotherapy agents like etoposide, teniposide, and intercalating agents.
• These drugs induce DNA cleavage by topoisomerase II, a process linked to cell death.
• Drug potency correlates with topoisomerase II activity, making it a unique chemotherapy target.

Purpose of the Study:

• To investigate topoisomerase II content and etoposide-induced DNA cleavage in primary human leukemia cells.
• To compare these findings with established human leukemia cell lines.
• To explore the relationship between topoisomerase II levels and cellular sensitivity to chemotherapy.

Main Methods:

• Assay of topoisomerase II content using immunoblotting with a mouse polyclonal antibody.
• Measurement of etoposide-induced DNA cleavage in patient-derived leukemia cells and cell lines.
• Analysis of drug uptake and cellular proliferation status (resting vs. mitogen-stimulated lymphocytes).

Main Results:

• Human leukemia cell lines (CCRF-CEM, HL-60, RPMI-7666) were significantly more sensitive to etoposide-induced DNA cleavage than primary leukemia cells from patients.
• Primary leukemia cells exhibited markedly reduced topoisomerase II content compared to cell lines, explaining their insensitivity.
• Proliferating lymphocytes, stimulated by phytohemagglutinin and interleukin-2, showed increased topoisomerase II content and etoposide sensitivity, similar to cell lines.

Conclusions:

• Topoisomerase II content is a key determinant of cellular sensitivity to etoposide and related chemotherapy agents.
• Differences in topoisomerase II levels between primary cells and cell lines may relate to proliferative status.
• Strategies to enhance topoisomerase II content could potentially improve the efficacy of these chemotherapeutic drugs.